Bruce L. Levine
Impact in
- Oncology top 0.01%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunology top 0.05%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
Papers in
- Oncology 156
- CAR-T cell therapy research 147
- Immunology 96
- Immune Cell Function and Interaction 55
- T-cell and B-cell Immunology 42
- Immunotherapy and Immune Responses 40
- Co-authors
- Carl H. June (178 shared papers)David L. Porter (38 shared papers)Michael Kalos (23 shared papers)Adam Bagg (4 shared papers)Stephan A. Grupp (42 shared papers)Anne Chew (25 shared papers)Simon F. Lacey (52 shared papers)J. Joseph Melenhorst (44 shared papers)
- Journals
- Blood (61 papers)Cytotherapy (23 papers)Journal of Clinical Oncology (19 papers)Molecular Therapy (7 papers)The Journal of Immunology (7 papers)
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Bruce L. Levine
256 papers receiving 33.3k citations
Bruce L. Levine's Hit Papers
Peers
Comparison fields: 5 of 171
- Oncology 22.9k
- Immunology 13.3k
- Virology 1.3k
- Genetics 7.4k
- Hematology 2.7k
Countries citing papers authored by Bruce L. Levine
This map shows the geographic impact of Bruce L. Levine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce L. Levine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce L. Levine more than expected).
Fields of papers citing papers by Bruce L. Levine
This network shows the impact of papers produced by Bruce L. Levine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce L. Levine. The network helps show where Bruce L. Levine may publish in the future.
Co-authors
The 25 scholars most cited alongside Bruce L. Levine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 261 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia Hit paper breakdown → | 2014 | 4107 |
| 2 | Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia Hit paper breakdown → | 2011 | 2792 |
| 3 | Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia Hit paper breakdown → | 2013 | 2745 |
| 4 | T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia Hit paper breakdown → | 2011 | 1870 |
| 5 | Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Hit paper breakdown → | 2015 | 1358 |
| 6 | Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas Hit paper breakdown → | 2017 | 1337 |
| 7 | Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV Hit paper breakdown → | 2014 | 1048 |
| 8 | Engineered T cells: the promise and challenges of cancer immunotherapy Hit paper breakdown → | 2016 | 853 |
| 9 | Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics Hit paper breakdown → | 2010 | 848 |
| 10 | Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies Hit paper breakdown → | 2013 | 727 |
| 11 | Global Manufacturing of CAR T Cell Therapy Hit paper breakdown → | 2017 | 578 |
| 12 | Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells Hit paper breakdown → | 2012 | 521 |
| 13 | T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans Hit paper breakdown → | 2013 | 493 |
| 14 | Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma Hit paper breakdown → | 2015 | 448 |
| 15 | Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial Hit paper breakdown → | 2018 | 401 |
| 16 | 2006 | 392 | |
| 17 | 2010 | 378 | |
| 18 | 2011 | 372 | |
| 19 | 1995 | 369 | |
| 20 | 1996 | 357 |
About Bruce L. Levine
Bruce L. Levine is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Genetics, having authored 261 papers that have together received 34.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (147 papers), Immune Cell Function and Interaction (55 papers), T-cell and B-cell Immunology (42 papers), Immunotherapy and Immune Responses (40 papers), Virus-based gene therapy research (33 papers), Chronic Lymphocytic Leukemia Research (26 papers), Viral Infectious Diseases and Gene Expression in Insects (23 papers) and CRISPR and Genetic Engineering (23 papers). The work is most often cited by research in Oncology (22.9k citations), Immunology (13.3k citations), Virology (1.3k citations), Genetics (7.4k citations) and Hematology (2.7k citations). Bruce L. Levine has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Carl H. June, David L. Porter, Michael Kalos, Adam Bagg, Stephan A. Grupp, Anne Chew, Simon F. Lacey, J. Joseph Melenhorst, David T. Teachey and David M. Barrett. Their work appears in journals such as Blood, Cytotherapy, Journal of Clinical Oncology, Molecular Therapy and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.